2689
Paraplegia following prophylactic intrathecal cytosine arabinoside (Ara-C) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg/m2/d for 5 consecutive days.
 a patient with acute myelogenous leukemia in remission: Subject; Paraplegia: Effect; prophylactic intrathecal cytosine arabinoside (Ara-C): Treatment; doses of 100 mg/m2/d for 5 consecutive days: Treatment; cytosine arabinoside: Treatment.Drug; intrathecal: Treatment.Route; acute myelogenous leukemia in remission: Treatment.Disorder; 100 mg/m2/d: Treatment.Dosage; 5 consecutive days: Treatment.Duration
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 a patient with acute myelogenous leukemia in remission: Subject; Paraplegia: Effect; prophylactic intrathecal cytosine arabinoside (Ara-C): Treatment; doses of 100 mg/m2/d for 5 consecutive days: Treatment; cytosine arabinoside: Treatment.Drug; intrathecal: Treatment.Route; acute myelogenous leukemia in remission: Treatment.Disorder; 100 mg/m2/d: Treatment.Dosage; 5 consecutive days: Treatment.Duration